slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,369
Current window 32,581-32,610
Pages 1,379
Rows per page 30
Component
32,581-32,610 of 41,369
06
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
21
The chart uses a regression line to correlate human and NHP half-lives, highlighting the 3.1x multiplier for YTE-modified antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
23
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
28
The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axis.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
31
The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
32
Includes two charts: a dose-response curve and a scatter plot of potency vs. binding specificity.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
33
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
37
The slide uses a biological process diagram to illustrate drug targets (a4b7, TL1A, IL-23) and their corresponding therapeutic antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
25
The chart displays percentages for OmniRat (54%), Omniflic (26%), OmniChicken (14%), OmniClic (3%), and OmniMouse/OmniTaur (3% combined).OmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
36
The slide uses a two-tier layout: top section for operational strategy and bottom section for stakeholder-centric values.OmniAb | Investor Presentation Deck | 39 slides · OmniAb
Pitch deck Investor relations Beat · Action1 hit
04
The central circle acts as a focal point connecting the four quadrants of business strengths.OmniAb | Results Presentation Deck | 17 slides · OmniAb
Conference presentation Investor relations Beat · What Is1 hit
10
OmniAb | Results Presentation Deck | 17 slidesOmniAb | Results Presentation Deck | 17 slides · OmniAb
Conference presentation Investor relations Beat · What Could BeLoop · So What Cascade1 hit
05
The slide uses a numbered list format to present strategic pillars.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Key Messages1 hit
11
The slide illustrates the transition from a 'Lease Run Down' model to a 'SaaS and Software Subscriptions' model, highlighting the shift in revenue and cash flow patterns.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
16
Includes detailed footnotes regarding definitions of bookings and TAM.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · KPI Overview1 hit
20
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
12
Overstock | Shareholder Engagement Presentation Deck | 14 slidesOverstock | Shareholder Engagement Presentation Deck | 14 slides · Overstock
Conference presentation Investor relations Beat · SatisfactionLoop · Golden Circle1 hit
13
Overstock | Shareholder Engagement Presentation Deck | 14 slidesOverstock | Shareholder Engagement Presentation Deck | 14 slides · Overstock
Conference presentation Investor relations Beat · Action1 hit
18
The slide highlights a weighted average entry multiple of 15.7x and a weighted average reduction of 3.2x.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
The table lists historical investment data including advances, recoupment rates, and returns.Reservoir | Investor Presentation Deck | 35 slides · Reservoir
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
12
The chart uses a stacked bar format to visualize cumulative growth.Sonos | Investor Presentation Deck | 20 slides · Sonos
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
20
The slide uses a visual metaphor of a smart speaker to illustrate the concept of 'anywhere' access to information.Taboola | Investor Presentation Deck | 64 slides · Taboola
Pitch deck Investor relations Beat · Satisfaction1 hit
41
Includes CAGR calculation and YoY growth metrics.Taboola | Investor Presentation Deck | 64 slides · Taboola
Pitch deck Investor relations 1 hit
16
Includes company branding and study logo.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
35
The slide uses a mathematical formula structure to explain revenue recognition.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
38
Uses a funnel diagram to illustrate market penetration.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
16
The slide explains the dual-class structure and how it relates to financial reporting and economic interest.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
08
Includes revenue from DR.WU (mainland China), Galénic, Eve Lom, Abby's Choice, and others.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Loop · So What Cascade1 hit
09
The slide highlights a 59% YoY growth in combined net revenues for the three brands.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Loop · So What Cascade1 hit
10
The chart highlights a strategic reduction in offline retail footprint throughout 2022.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations 1 hit